Profile data is unavailable for this security.
About the company
X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4, that is being developed as an oral, once-daily therapy. It has developed a pipeline of small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
- Revenue in USD (TTM)563.00k
- Net income in USD17.63m
- Incorporated2010
- Employees93.00
- LocationX4 Pharmaceuticals Inc61 NORTH BEACON STREET, 4TH FLOORBOSTON 02134United StatesUSA
- Phone+1 (857) 529-8300
- Fax+1 (302) 655-5049
- Websitehttps://www.x4pharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ALX Oncology Holdings Inc | 0.00 | -171.44m | 86.91m | 74.00 | -- | 0.5432 | -- | -- | -3.64 | -3.64 | 0.00 | 3.04 | 0.00 | -- | -- | 0.00 | -74.45 | -34.34 | -84.76 | -36.47 | -- | -- | -- | -7,238.76 | -- | -- | 0.0734 | -- | -- | -- | -30.23 | -- | 14.30 | -- |
Genelux Corp | 8.00k | -26.54m | 88.07m | 23.00 | -- | 2.31 | -- | 11,008.18 | -0.9704 | -0.9704 | 0.0003 | 1.11 | 0.0002 | -- | -- | 347.83 | -69.34 | -- | -84.43 | -- | -- | -- | -331,725.00 | -- | -- | -- | 0.00 | -- | -98.46 | -- | -443.44 | -- | -- | -- |
CytomX Therapeutics Inc | 119.57m | 11.09m | 89.05m | 120.00 | 8.31 | -- | 6.86 | 0.7448 | 0.1371 | 0.1371 | 1.45 | -0.3997 | 0.6491 | -- | 51.12 | 996,408.30 | 6.02 | -21.53 | 26.34 | -32.32 | -- | -- | 9.27 | -100.38 | -- | -- | -- | -- | 90.38 | 11.21 | 99.43 | -- | -26.01 | -- |
Hillevax Inc | 0.00 | -156.27m | 89.61m | 90.00 | -- | 0.4329 | -- | -- | -3.38 | -3.38 | 0.00 | 4.16 | 0.00 | -- | -- | 0.00 | -55.47 | -- | -63.02 | -- | -- | -- | -- | -- | -- | -- | 0.1113 | -- | -- | -- | 22.68 | -- | -- | -- |
X4 Pharmaceuticals Inc | 563.00k | 17.63m | 91.16m | 93.00 | 6.31 | 0.9634 | 5.05 | 161.92 | 0.0857 | 0.0857 | 0.0028 | 0.5616 | 0.0029 | -- | 0.6726 | 6,053.76 | 9.18 | -61.53 | 10.59 | -69.20 | 52.40 | -- | 3,131.79 | -13,288.93 | 6.04 | -- | 0.4427 | -- | -- | -- | -4.93 | -- | 12.03 | -- |
Allovir Inc | 0.00 | -140.34m | 91.44m | 112.00 | -- | 0.7598 | -- | -- | -1.23 | -1.23 | 0.00 | 1.04 | 0.00 | -- | -- | 0.00 | -67.85 | -52.85 | -73.72 | -57.72 | -- | -- | -- | -378,613.90 | -- | -- | 0.00 | -- | -- | -- | -12.87 | -- | -- | -- |
Assembly Biosciences Inc | 21.48m | -45.61m | 91.50m | 65.00 | -- | 2.64 | -- | 4.26 | -9.32 | -9.32 | 4.28 | 5.47 | 0.2362 | -- | 125.62 | 330,476.90 | -50.15 | -39.69 | -69.22 | -44.03 | -- | -- | -212.33 | -409.24 | -- | -- | 0.00 | -- | -- | -13.51 | 34.23 | -- | -5.59 | -- |
Leap Therapeutics Inc | 0.00 | -60.34m | 91.83m | 54.00 | -- | 1.40 | -- | -- | -2.00 | -2.00 | 0.00 | 1.72 | 0.00 | -- | -- | 0.00 | -67.81 | -80.06 | -80.19 | -95.03 | -- | -- | -- | -7,900.37 | -- | -- | 0.00 | -- | -- | -- | -49.12 | -- | -- | -- |
Ikena Oncology Inc | 1.84m | -66.71m | 92.87m | 18.00 | -- | 0.5743 | -- | 50.36 | -1.43 | -1.43 | 0.0393 | 2.96 | 0.0112 | -- | -- | 42,883.72 | -40.52 | -29.72 | -43.17 | -34.62 | -- | -- | -3,617.57 | -294.90 | -- | -- | 0.00 | -- | -41.35 | 56.05 | 0.8711 | -- | 6.30 | -- |
Avalo Therapeutics Inc | 807.00k | -36.22m | 93.24m | 19.00 | -- | -- | -- | 115.54 | -63.82 | -63.82 | 0.3347 | -2.08 | 0.0122 | -- | 20.96 | 42,473.68 | -54.66 | -99.64 | -529.15 | -154.42 | 64.19 | 84.69 | -4,488.60 | -613.58 | -- | -- | -- | -- | -89.34 | -22.83 | 24.28 | -- | -22.48 | -- |
bluebird bio Inc | 54.90m | -311.44m | 94.47m | 375.00 | -- | 1.78 | -- | 1.72 | -2.19 | -2.19 | 0.3574 | 0.2733 | 0.0909 | 3.21 | -- | 146,400.00 | -51.54 | -34.75 | -80.31 | -40.84 | -37.34 | -124.35 | -567.29 | -5,770.41 | 0.5712 | -19.81 | 0.7827 | -- | 720.04 | -11.58 | 8.00 | -- | -30.47 | -- |
MDxHealth SA | 80.74m | -40.80m | 94.58m | 300.00 | -- | -- | -- | 1.17 | -1.54 | -1.54 | 3.06 | -0.3229 | 0.5906 | 9.39 | 7.49 | 269,136.70 | -29.85 | -51.62 | -43.63 | -64.72 | 62.64 | 50.88 | -50.54 | -117.64 | 0.8252 | -1.74 | 1.18 | -- | 89.43 | 19.84 | 2.14 | -- | 30.13 | -- |
Oramed Pharmaceuticals, Inc. | 0.00 | 20.86m | 94.99m | 15.00 | 4.66 | 0.5346 | 4.53 | -- | 0.4999 | 0.4999 | 0.00 | 4.36 | 0.00 | -- | -- | 0.00 | 12.19 | -- | 12.29 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -50.43 | -- | 115.11 | -- | -- | -- |
Beyondspring Inc | 1.88m | -15.57m | 95.20m | 35.00 | -- | -- | -- | 50.75 | -0.3987 | -0.3987 | 0.0481 | -0.749 | 0.0698 | -- | -- | 52,111.11 | -59.75 | -75.50 | -102.15 | -96.48 | -- | -- | -856.29 | -4,977.12 | -- | -- | -- | -- | 29.61 | -- | 36.82 | -- | -13.54 | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 31 Mar 2024 | 8.06m | 4.80% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 7.66m | 4.56% |
Soleus Capital Management LP (Investment Management)as of 31 Mar 2024 | 4.58m | 2.73% |
Adage Capital Management LPas of 31 Mar 2024 | 4.28m | 2.55% |
Sio Capital Management LLCas of 31 Mar 2024 | 3.59m | 2.14% |
Perceptive Advisors LLCas of 31 Mar 2024 | 3.55m | 2.11% |
Geode Capital Management LLCas of 30 Jun 2024 | 3.52m | 2.09% |
Kingdon Capital Management LLCas of 31 Mar 2024 | 3.47m | 2.07% |
AXA Investment Managers UK Ltd.as of 31 Mar 2024 | 3.07m | 1.83% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.52m | 1.50% |